SCHEDULE 13G/A 0001104659-24-110632 0001869128 XXXXXXXX LIVE 1 Common Stock, par value $0.0001 per share 09/30/2025 0001736730 CAMP4 THERAPEUTICS CORPORATION 13463J101 One Kendall Square Building 1400 West, 3rd Floor Cambridge MA 02139 Rule 13d-1(c) Northpond Ventures II, LP b DE 0.00 1003193.00 0.00 1003193.00 1003193.00 2.1 PN Northpond Ventures II GP, LLC b DE 0.00 1003193.00 0.00 1003193.00 1003193.00 2.1 OO Northpond Ventures III, LP b DE 0.00 763636.00 0.00 763636.00 763636.00 1.6 PN Northpond Ventures III GP, LLC b DE 0.00 763636.00 0.00 763636.00 0.00 1.6 OO Northpond Ventures, LP b DE 0.00 471415.00 0.00 471415.00 471415.00 1.0 PN Northpond Ventures GP, LLC b DE 0.00 471415.00 0.00 471415.00 471415.00 1.0 OO Michael P. Rubin b X1 0.00 2238244.00 0.00 2238244.00 2238244.00 4.8 IN CAMP4 THERAPEUTICS CORPORATION One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA, 02139. The names of the persons filing this report (collectively, the "Reporting Persons") are: Northpond Ventures II, LP ("Northpond Fund II") Northpond Ventures II GP, LLC ("Northpond II GP") Northpond Ventures III, LP ("Northpond Fund III") Northpond Ventures III GP, LLC ("Northpond III GP") Northpond Ventures, LP ("Northpond Fund I") Northpond Ventures GP, LLC ("Northpond GP") Michael P. Rubin ("Rubin") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G. The principal business office of each Reporting Person is: 7500 Old Georgetown Road, Suite 800 Bethesda, MD 20814 Northpond Fund II Delaware Northpond II GP Delaware Northpond Fund III Delaware Northpond III GP Delaware Northpond Fund I Delaware Northpond GP Delaware Rubin United States Y Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference. The Reporting Persons ownership of the Issuer's securities includes (i) 1,003,193 shares of common stock directly held by Northpond Fund II; (ii) 763,636 shares of common stock directly held by Northpond Fund III; and (iii) 471,415 shares of common stock directly held by Northpond Fund I. Northpond II GP is the general partner of Northpond Fund II, Northpond III GP is the general partner of Northpond Fund III, and Northpond GP is the general partner of Northpond Fund I. Rubin is the managing member of each of Northpond II GP, Northpond III GP and Northpond GP and has voting and dispositive power over the securities held by each of Northpond Fund II, Northpond Fund III and Northpond Fund I. Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference. The percentage set forth in each row 11 is based upon 46,880,185 shares of common stock outstanding as of September 30, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 6, 2025. Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference. Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference. Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference. Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference. N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit A to the Reporting Persons' Schedule 13G filed with the SEC on October 22, 2024). Northpond Ventures II, LP /s/ Patrick Smerkers 11/14/2025 Northpond Ventures II GP, LLC /s/ Patrick Smerkers 11/14/2025 Northpond Ventures III, LP /s/ Patrick Smerkers 11/14/2025 Northpond Ventures III GP, LLC /s/ Patrick Smerkers 11/14/2025 Northpond Ventures, LP /s/ Patrick Smerkers 11/14/2025 Northpond Ventures GP, LLC /s/ Patrick Smerkers 11/14/2025 Michael P. Rubin /s/ Michael P. Rubin 11/14/2025